Background {#Sec1}
==========

Coronary artery disease (CAD) is characterized by the occlusion or stenosis of coronary artery mostly caused by atherosclerosis, and is one of the leading causes of mortality in humans \[[@CR1], [@CR2]\]. Patients with CAD are vulnerable in development of major cardiovascular events (MACEs) including nonfatal acute myocardial infarction, unstable angina, stroke, transient ischemic attack, peripheral arterial occlusive disorder, and death \[[@CR3]\]. According to previous long-term follow-up studies, the incidence of MACEs development after CAD ranges from 21 to 49% \[[@CR4]\], while the recurrence rates of MACEs are up to 75% within 3 years \[[@CR5]\]. These events are typically caused by the formation of thrombus and insufficient blood supply. Identifying risk factors for the development of MACEs is of great value in the prognosis of CAD patients.

Von Willebrand factor (vWF) is a large multimeric glycoprotein required for the formation of hemostatic plugs and arterial thrombi \[[@CR6]\]. vWF adheres platelets to the blood vessel wall, and acts as a plasma carrier for factor VIII to prevent its degradation in the blood circulation \[[@CR7], [@CR8]\]. After synthesis, vWF is stored in the Weibel-Palade bodies of endothelial cells and the α-granules of platelets \[[@CR9], [@CR10]\]. The stored vWF is rapidly released at moments of endothelial cell damage, thus it is considered as a promised biomarker for endothelial dysfunction \[[@CR11]\]. In addition, studies have shown that the plasma vWF derived from coronary vascular endothelial cells is significantly elevated when coronary artery injury occurs \[[@CR12]\], indicating a pathogenesis role of vWF in the progression of CAD. Increased level of vWF has been recognized as an independent predictor of CAD in general population \[[@CR9]\]. However, the prognostic role of vWF in CAD patients remains controversial. Several studies demonstrate a weak association between elevated vWF level and adverse outcomes in patients with CAD \[[@CR13]\]. The current meta-analysis was performed to evaluate the prognostic value of plasma vWF in patients with CAD, in terms of MACEs.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We searched for all publications concerning the association between vWF and CAD up to July 2018. The literatures were searched in PubMed, Embase database and CNKI. The search strategy was composed by the following search terms (vWF OR Willebrand Protein OR von Willebrand Factor OR Factor VIIIR-Ag) AND (Coronary Disease OR coronary artery disease OR CAD OR CHD OR Myocardial Infarction OR AMI OR Acute coronary syndrome OR ACS OR angina) AND (major adverse cardiac events OR mortality OR death OR prognosis).

Study selection {#Sec4}
---------------

Inclusion criteria were as follows: (1) cohort studies enrolling patients with CAD (myocardial Infarction, acute coronary syndrome and stable CAD); (2) data on plasma vWF was reported; (3) MACEs or mortality following CAD were recorded; (4) studies written in English or Chinese. Exclusion criteria are as follows: (1) patients without CAD; (2) there is no definitive value of plasma vWF.

Data extraction {#Sec5}
---------------

Two independent reviewers extracted the following data from each eligible studies: first author's name, year of publication, mean age, sample size, gender, mean and standard deviation (mean ± SD) or mean and standard error (mean ± SE) of plasma vWF concentration, definition of MACEs, mean or median follow-up duration, treatment modality, data regarding baseline and follow-up concentrations of vWF. Moreover, if the articles provide the data of median and interquartile range (IQR) format or mean and *p* value, we calculated the SMD according to the formulations recommended by Cochrane Handbooks. Any discrepancy in data extraction was resolved through discussion with a third reviewer.

Quality assessment {#Sec6}
------------------

Two independent authors assessed the methodological quality according to the Newcastle-Ottawa Quality Assessment scale (NOS) for cohort study. Total NOS score ranged from 0 to 9 stars. Those scored ≥7 stars were considered as high quality and those scored ≤5 as low quality.

Statistical analysis {#Sec7}
--------------------

Meta-analyses were conducted on Review Manager software (RevMan5.3, Cochrane Collaboration, Oxford, UK, <http://community.cochrane.org>) and STATA software (Stata Corp, College Station, Texas, USA). The SMD and 95% confidence intervals were calculated using a generic inverse variance approach. The overall effects were determined by Z-test and *P*-value \< 0.05 were considered as statistically significant.

The heterogeneity across studies was tested by CochranQ statistics and I^2^ statistics. A random-effects model was used due to significant heterogeneity. Subgroup analyses were conducted to identify the source of potential heterogeneity based on the duration of follow-up, PCI, and severity of CAD. Meta-regression was also conducted to explore the potential heterogeneity. *P* \< 0.05 was considered statistically significant. Sensitivity analysis was performed by removing studies one by one to estimate the stability of meta-analysis.

Results {#Sec8}
=======

Search results and characteristics of included studies {#Sec9}
------------------------------------------------------

A total of 1382 publications were identified by the search strategy, and 1324 publications remained in this study after removal of duplicates. After carefully reviewing the titles and abstracts, 44 candidate articles were screened out for further full-text reading, and 1280 unrelated articles were excluded. In addition, 27 full-text reviewed articles were excluded due to disqualification of inclusion criteria, 15 studies were included in this meta-analysis. Search progress was shown in Fig. [1](#Fig1){ref-type="fig"}. Of these 15 studies, 4 studies were conducted in China, 3 in Austria, 3 in UK, 2 in Germany, 1 in USA, 1 in Norway and 1 in France. A total of 4184 patients with CAD were identified and analyzed. Individual study sample sizes varied from 58 to 1045, and the duration of follow-up ranged from 30 days to 13 years. The included studies provided the plasma level of vWF at different time points after CAD (on admission, 24 h, 48 h). The main characteristics of the studies were shown in Table [1](#Tab1){ref-type="table"}. Fig. 1The flow chart of the literature search and selection processTable 1Characteristics of the studies included in the meta-analysisYearAuthorBlood Sampling SchedulePatientsAge, y C/CTLSample size C/CTLTreatment modalityDefinition of MACEsMeasuring MethodsRates of HF C/CTLFollow up2016HAMID24 hSTEMI57/5317/61PCI, ThrombolyticAll-cause mortality, recurrent nonfatal MI, or HF and the secondary endpoint of early adverse LV remodelingELISANR30 days2015LiuAdmissionSTEMI58/6030/102PCIRecurrent MI, heart failure readmission, unplanned repeat revascularization, malignant dysrhythmia, stroke, or pulmonary embolismELISANR1 year2013LeuAdmissionCAD68/6733/42AntiplateletCV death, nonfatal AMI, unstable angina, stroke, transient ischemic attack, or peripheral arterial occlusive disorderELISANR40 months2013HyseniAdmissionACS67.5/ 76.8293/46PCI, AntithromboticAll-cause mortalityELISANR4 years2008YuAdmission, 12 h, 48 hACS68/6422/48AnticoagulationDeath, MI or recurrent MI, and recurrent anginaELISANR30 days2008BOOS24 hACS69/60.642/169Thrombolysis, PCICV death, non-fatal MI, readmission with acute HF and stroke, and CV death separately.ELISA28.6 / 7.6338 days2006Fuchs24 hACS60/5758/150PCI, ThrombolysisRecurrent non-fatal MI (STEMI and NSTE-MI)TurbidometryNR28 months2006An24 hACSNR21/59NRNon-fatal reinfarction, non-fatal heart failure, recurrent angina attacks, drug intensification or emergency revascularization, and cardiac deathELISANR30 days2005LeeAdmission, 48 hACS67/7024/34Antiplatelet, AnticoagulationDeath, MI, and refractory angina requiring revascularisationELISA8 /630 days2005Warlo24 hCADNR73/927AntiplateletUnstable angina pectoris, MI, non haemorrhagic stroke and deathNRNR2 years2003NiessnerAdmissionCAD56/52103/38NRAll-cause mortality and MI, revascularization procedures including PTCA with/without coronary stenting and ACBG.ELISANR13 years2002EikelboomAdmissionACSNR78/407Anticoagulant, AntiplateletCV death, MI, stroke or refractory ischaemiaNRNR30 days2000RedondoAdmissionCAD59/5737/157NRFatal MI, non-fatal MI, percutaneous transluminal coronary angioplasty or CABG.ELISANR2 years1999MossAdmissionMI59/4781/964NRDeath due to coronary heart disease or recurrent nonfatal MIELISANR26 months1998MontalescotAdmission, 48 hCAD70/7048/20AntiplateletDeath, MI, recurrent angina, or revascularizationELISANR30 days*Abbreviations*: *ACBG* aorto coronary bypass graft, *ACS* acute coronary syndromes, *AMI* acute myocardial infarction, *CABG* coronary artery bypass grafting, *C/CTL* case/control group, *CV* cardiovascular, *ELISA* enzyme-linked immunosorbent assay, *HF* heart failure, *NR* unreported, *LV* left ventricular, *MI* myocardial infarction, *non-STEMI* non-ST-elevated myocardial infarction, *PCI* percutaneous coronary intervention, *PTCA* percutaneous transluminal coronary angioplasty, *STMI* ST-elevated myocardial infarction

Plasma vWF and MACEs {#Sec10}
--------------------

The meta-analyses were conducted according to the time points of vWF examination (on admission, 24 h and 48 h after admission). Consistent with previous reports, we found that the plasma level of vWF is elevated in CAD patients. The result of meta-analyses further to reveal that plasma level of vWF is significantly higher in CAD patients with MACEs than those without MACEs (Fig. [2](#Fig2){ref-type="fig"}). The pooled SMD for vWF examined at 24 h and 48 h after admission was 0.55 (95% CI = 0.30--0.80, *P* \< 0.0001) and 0.70 (95% CI = 0.27--1.13, *P* = 0.001), respectively. However, there was no significant difference in plasma level of vWF examined on admission between the two groups. The pooled SMD was − 0.25 (95% CI = − 0.75-0.06, *P* = 0.12). In addition, heterogeneity across studies was present. Fig. 2Forest plot of meta-analysis of plasma vWF after MACEs. Each block represents a study and the area of each block is proportional to the weight of that study. The horizontal line represents each study's 95% confidence interval (CI) for the effect. The centre of the diamond is the pooled effect across studies, and the width of the diamond denotes its 95% CI. CAD, coronary artery disease; MACEs: major adverse cardiac events; IV, invers variance; SD, standard deviation

Quality evaluation {#Sec11}
------------------

Four studies \[[@CR3], [@CR4], [@CR14], [@CR15]\] with 8 NOS scores and eight studies \[[@CR10], [@CR16]--[@CR22]\] with 7 NOS scores were considered as good quality. Other studies \[[@CR13], [@CR23], [@CR24]\] achieved 6 scores indicating moderate quality. The results of the quality assessment of the included studies were shown in Table [2](#Tab2){ref-type="table"}. Table 2Quality assessment of the included studies based on the Newcastle--Ottawa ScaleAuthorStudy designSelectionComparabilityOutcomeTotal scoresHAMIDCohort study3227LiuCohort study3238LeuCohort study3238HyseniCohort study3126yuCohort study3227BOOSCohort study3238FuchsCohort study2226AnCohort study2226LeeCohort study3238WarloCohort study2237NiessnerCohort study3227EikelboomCohort study3227RedondoCohort study3227MontalescotCohort study2237MossCohort study2237

Heterogeneity {#Sec12}
-------------

Subgroup analyses were conducted to evaluate potential sources of heterogeneity. Include studies were subgrouped according to the duration of follow-up. As shown in Table [3](#Tab3){ref-type="table"}, the pooled effects of the meta-analyses were not reversed by the duration of follow-up. However, when subgrouped by the severity of CAD, a significant difference in SMD in vWF plasma levels examined at 24 h after admission was found between the subgroups. The pooled SMD was 0.67 (95% CI = 0.47--0.86, *P* \< 0.00001) for acute coronary syndrome (ACS) and myocardial infarction (MI) patients and was 0.21 (95% CI = − 0.03-0.45, *P* = 0.09) for stable CAD patients. No significant difference in SMD in vWF plasma levels examined at 24 h after admission was found between patients treated with PCI (SMD = 0.63, 95% CI = 0.42--0.84, *P* \< 0.00001) and those without PCI (SMD = 0.33, 95% CI = 0.11--0.54, *P* = 0.003). To validate the results from subgroup analyses, we performed meta-regression to determine the source of heterogeneity. The associations between types of coronary disease, high range of follow up sample size, patients treated with PCI and the utilization of antiplatelet or anticoagulation were evaluated. As shown in Table [4](#Tab4){ref-type="table"}, types of coronary disease, high range of follow up sample size, patients treated with PCI, and the utilization of antiplatelet or anticoagulation were not the source of heterogeneity in vWF plasma levels examined on admission (types of coronary disease: *P* = 0.489; high range of follow up sample size: *P* = 0.364; patients treated with PCI: *P* = 0.725; the utilization of antiplatelet: *P* = 0.527; the utilization of anticoagulation drugs: *P* = 0.509). However, both high range of follow up sample size and the utilization of antiplatelet or anticoagulation contribute to heterogeneity in vWF plasma levels examined at 24 h after admission (high range of follow up sample size: *P* = 0.033; the utilization of antiplatelet or anticoagulation: *P* = 0.007). Table 3Subgroup analyses on MACEsSubgroupNo. of studiesNo. of subjectsMeta-analysisHeterogeneityMACEsNon MACEsSMD95% CI*P*I^2^ (%)*P*Follow-up duration On admission\< 1 year4172509−0.57−1.44-0.30.293\< 0.00001≥1 year65771349−0.10−0.39-0.190.5760.0007 24 h\< 1 year2381200.760.38--1.13\< 0.000100.47≥1 year317312460.480.17--0.780.002690.04Type of CAD On admissionCAD4221257−0.20−0.42-0.010.0693\< 0.00001ACS、MI65281601−0.09−0.22-0.040.16760.04 24 hCAD1739270.21−0.03-0.450.09ACS、MI41384390.670.47--0.86\< 0.0000100.86PCI On admissionYes2323148−0.46−0.99-0.070.09760.04No84261710−0.20−0.55-0.150.27860.00001 24 hYes31173800.630.42--0.84\< 0.0000101No2949860.330.11--0.540.003820.02*Abbreviations No* number, *MI* myocardial infarction, *SMD* standardized mean difference, *NR* unreported, *CI* confidence interval, *ACS* acute coronary syndromes, *CAD* coronary artery disease, *MACEs* major adverse cardiac eventsTable 4Source of heterogeneity by meta-regression analysisFactorsCoefficientStandard error*P*Follow-up duration On admission0.45946060.47699950.364 24 h0.73992350.19798340.033Type of CAD On admission−0.35374440.48805350.489 24 h0.46330340.15749120.06PCI On admission−0.22097720.60577070.725 24 h0.30646620.22276910.263Regular anticoagulant drugs On admission0.36083040.52229920.509 24 h0.67219090.10002110.007Antiplatelet On admission−0.32526590.49137010.527 24 h0.67219090.10002110.007

Sensitivity analyses {#Sec13}
--------------------

Each study was excluded sequentially to evaluate the influence of an individual study on the results. No study fundamentally changed the combined effects at any time points. Furthermore, the study by Warlo \[[@CR10]\] was found to be the source of heterogeneity. When the study was eliminated from analysis, heterogeneity become minimal (examined on 24 h: SMD = 0.67, 95% CI = 0.47--0.86, *P* \< 0.00001, I^2^ = 0%).

Publication bias {#Sec14}
----------------

Funnel plot was performed to evaluate the publication bias of literatures. As shown in Fig. [3](#Fig3){ref-type="fig"}. Fig. 3Funnel plot of publication bias. No publication bias was presented in any groups. **a** Funnel plot of studies on admission of vWF levels. **b** Funnel plot of studies at 24 h after admission of vWF levels. **c** Funnel plot of studies at 48 h after admission of vWF levels

Discussion {#Sec15}
==========

This meta-analysis summarizes evidence for association between high-circulation vWF levels and clinically adverse outcomes in patients with CAD. The data on plasma vWF at three time points was included. Results indicated that the plasma vWF was significantly increased in the adverse event group on 24 h and 48 h after primary CAD. However, the level of vWF on admission showed no significant difference between the two groups. Subgroup analyses revealed that the association of increased vWF level with short-term MACEs is stronger. In addition, increased vWF level displays a positive association on MACEs in ACS and MI other than stable CAD. Together, our results suggested that plasma level of vWF is an indicator for the risk of MACEs among patients with CAD.

vWF is mainly synthesized in endothelial cells \[[@CR25], [@CR26]\]. Upon endothelial cell injury, vWF is released into the blood circulation. In blood plasma, vWF binds to platelet receptors GPIb-IX-V, GPIIb/IIIa and GPIb to promote thrombosis \[[@CR27], [@CR28]\]. The combination of vWF and collagen causes a conformational change in the site of vWF binding to factor VIII, which promotes fibrin agglutination \[[@CR29], [@CR30]\]. VWF also mediates platelet adhesion on activated endothelial cells, enhancing thrombus formation even in the absence of endothelial denudation \[[@CR31]\]. Several studies have reported that high plasma vWF levels are associated with endothelial dysfunction and inflammation \[[@CR32], [@CR33]\], which contribute to the cardiovascular risks. In addition, vWF involves in the pathogenesis of atherosclerosis \[[@CR34]\].

MACEs, such as nonfatal myocardial infarction, nonfatal stroke, or target vessel revascularization, are more likely to occur in patients with severe CAD \[[@CR3]\]. The increased risk of vWF for MACEs in CAD may be caused by prothrombotic or hypercoagulable conditions, which promote the formation of occlusive thrombus \[[@CR35]\]. Both acute myocardial infarction (AMI) and stroke are precipitated by an occlusive thrombus on a preexisting atherosclerotic plaque \[[@CR36]\]. VWF promotes thrombus formation by mediating platelet adhesion and aggregation \[[@CR36]\]. The inflammatory response involved in the progression of atherosclerotic plaques may also promote an increased secretion of vWF \[[@CR37]\]. Therefore, vWF may be considered as a potential clinical biomarker. Previous studies reported that PCI leads to a significant increase of vWF levels compared with the pre-procedural levels \[[@CR38]\]. PCI itself causes endothelial cell damage due to mechanical injury by catheter manipulations \[[@CR39]\]. In addition, hemodynamic effects of transient myocardial injury during PCI contributes to the increased vWF levels \[[@CR40]\].

The prognostic role of vWF in patients with CAD is even more convinced than other acute phase-reactive proteins such as his-CRP and fibrinogen \[[@CR41]\]. Studies have shown that elevated early vWF levels in patients with CAD are an independent predictor of adverse events over the next 2 weeks to 1 month, whereas other acute phase response proteins are not \[[@CR42]\]. Compared with reactive proteins, vWF is released locally during vascular injury without new synthesis of proteins. Recent case-control studies also demonstrated that the higher plasma vWF or lower ADAMTS13 levels were closely associated with the risk of MI \[[@CR33], [@CR43]--[@CR45]\], ischaemic stroke \[[@CR46]\]. However, the present study is the first meta analysis that highlights the long-term prognostic value of plasma vWF levels in patients with CAD.

Our study has several advantages. First, vWF is a promised indicator of the clinical outcome in patients with coronary artery disease. The dramatic increase of plasma vWF implies its potential roles in the diagnosis of CAD. Second, all the studies included in this meta-analysis were medium-to-high quality as assessed by Newcastle-Ottawa Quality Assessment Scale. Third, publication bias assessment confirmed the robustness and reliability of our results. Moreover, circulating vWF level was collected on admission, 24 h and 48 h after primary CAD respectively, which provides a variation of vWF with the progression of disease. Our study has several limitations. First, the number of studies of duration on 24 h or 48 h available for meta analyzes was relatively small. Second, the articles included many types of coronary artery disease including acute coronary syndrome, myocardial infarction, angina, which may contributes to clinical heterogeneity. Third, detailed information regarding symptom duration was not available in several studies.

Conclusion {#Sec16}
==========

Plasma vWF levels of CAD patients examined at 24 h and 48 h after admission might be an independent prognostic factor for MACE. However, many studies had incomplete information, and more studies with more detailed data and sufficient sample size are necessary to confirm our findings.
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